Etodolac, A Preferential COX-2 Inhibitor, does not Inhibit Platelet Aggregation in a Randomized Placebo-Controlled Trial
Jan 2013 DOI 10.14302/issn.2328-0182.japst-12-99
Wolfgang C KorteCorresponding author
To date, platelet aggregation studies have not been formally evaluated in persons receiving Etodolac, a preferential cyclooxygenase-2 (COX-2) inhibitor. Our purpose was to investigate the influence of Etodolac in therapeutic (analgesic) doses (300 mg every 12h) on platelet aggregation as compared to…